News FocusTISSUE ENGINEERING

Mending the Youngest Hearts

See allHide authors and affiliations

Science  26 Aug 2011:
Vol. 333, Issue 6046, pp. 1088-1089
DOI: 10.1126/science.333.6046.1088

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

This month, after an arduous approval process, surgeons are testing tissue-engineered cardiac blood vessels in the first U.S. patients. The implants, which are used to connect a major cardiac vein and the artery that carries blood to the lungs, are made of a synthetic scaffold seeded with cells from the patient's own bone marrow. In the body, the graft develops into a living blood vessel that grows with the patient. But new experiments suggest that inflammation, long seen as an enemy of transplants and artificial implants alike, seems to play a key role in the transformation of the cell-filled scaffold into a healthy blood vessel. And stem cells, which have been seen as the stars of tissue engineering, play a less significant role than expected. The results are prompting tissue engineers to rethink the role of inflammation and stem cells.